At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease and Controls
In Brief
A Phase 2 clinical trial evaluating (11C)PE2I and Ioflupane for Parkinson Disease and 2 related conditions. Completed, enrolled 82 participants across 1 site.
Detailed Summary
Prospective, single center study to determine whether the current R2\* iron mapping method for measuring nigral iron changes in the brain can be significantly improved by using the Quantitative Susceptibility Mapping (QSM) based iron mapping techniques with the goal of validating QSM for potential use in later clinical trials. Subjects with a diagnosis of Parkinson's Disease, Rapid Eye Movement (REM) Sleep Behavior Disorder, and Normal Volunteers who meet the inclusion and exclusion criteria will be eligible for participation in this study.
Study Details
Timeline
Interventions
Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits